InvestorsHub Logo
Followers 6
Posts 88
Boards Moderated 0
Alias Born 02/27/2010

Re: None

Sunday, 05/31/2015 10:32:53 AM

Sunday, May 31, 2015 10:32:53 AM

Post# of 955
Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting -


"Of the 16 patients with DLBCL enrolled across the dose escalation and expansion phases of the study, 10 were evaluable for disease response at the time of data cut-off. The best responses observed in these patients were CR (2 patients), PR (4 patients) SD (2 patients) and progressive disease, or PD (2 patients),

- See more at: http://globenewswire.com/news-release/2015/05/31/740644/10136647/en/Curis-Reports-CUDC-907-Data-From-the-Ongoing-Phase-1-Trial-at-the-2015-ASCO-Annual-Meeting.html#sthash.66CEhNXD.dpuf


"Although there are more than 50 types of NHL, diffuse large B cell lymphoma (DLBCL) is the most common type, making up about 30 percent of all lymphomas. In the United States, DLBCL affects about 7 out of 100,000 people each year."

http://www.uptodate.com/contents/diffuse-large-b-cell-lymphoma-in-adults-beyond-the-basics
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRIS News